275-24254-29220
4 vaccinations
2 coded responses
44 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 41-45
- ZIP prefix
- 231 / VA
- Registered
- 2020-12-21
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-21
Registered in v-safe
-
2020-12-21
Dose 1 — Pfizer-BioNTech
- 2020-12-21
- 2020-12-22
- 2020-12-23
- 2020-12-25
- 2020-12-26
- 2020-12-27
- 2020-12-28
- 2021-01-04
-
2021-01-11
Dose 2 — Pfizer-BioNTech
- 2021-01-11
- 2021-01-12
- 2021-01-13
- 2021-01-14
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-18
- 2021-01-25
- 2021-02-01
- 2021-02-08
- 2021-02-15
- 2021-02-22
- 2021-04-13
- 2021-07-12
-
2021-09-28
Dose 3 — Pfizer-BioNTech
- 2021-09-29
-
2021-09-30
Health check-in — days 1–6 daily, dose 3Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-10-01
- 2021-10-02
- 2021-10-03
- 2021-10-04
- 2021-10-05
- 2021-10-12
- 2021-10-19
- 2021-10-26
- 2021-11-02
- 2021-11-09
- 2021-12-28
- 2022-03-31
-
2022-09-12
Dose 4 — Pfizer-BioNTechCo-administered: Flu
- 2022-09-28
- 2022-10-09
- 2022-10-10
- 2022-10-17
- 2022-10-24
-
2022-12-12
Survey response — 3 months, dose 4MedDRA: Respiratory tract congestion — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Head and chest congestionMedDRA releases: 2024-11 · check-in free text available
-
2023-03-13
Survey response — 6 months, dose 4MedDRA: Fatigue, Oropharyngeal pain, Upper-airway cough syndrome — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitMedDRA releases: 2024-11
-
2023-03-13
Report sent to call center — 6 months, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
- 2023-03-15
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-21 | Pfizer-BioNTech | |
| 2 | 2021-01-11 | Pfizer-BioNTech | |
| 3 | 2021-09-28 | Pfizer-BioNTech | No |
| 4 | 2022-09-12 | Pfizer-BioNTech | Flu |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2023-03-13 | Unsuccessful |
Free text
Release 12 — 3 months, dose 4
Symptoms: Head and chest congestion
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Fatigue | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Upper-airway cough syndrome | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release